Trial · NCT04033926
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment Period | 16 weeks in each Treatment Period (32 weeks total) | For the first 16 weeks, analysis was done for Treatment Period 1. For the second 16 weeks, analysis was done for Treatment Period 2. | score on a scale | MEAN |
| SECONDARY | Proportion of Patients With TIS Response | 16 weeks in each Treatment Period (32 weeks total) | participants | NUMBER | |
| SECONDARY | Number of Patients Meeting the International Myositis Assessment and Clinical Studies Group (IMACS) Definition of Improvement (DOI) | 16 weeks in each Treatment Period (32 weeks total) | participants | NUMBER | |
| SECONDARY | Mean Percent Change From Baseline From Start to End of Treatment in the IMACS Individual CSAMs | 16 weeks in each Treatment Period (32 weeks total) | Some values were not collected for participants. | percent change | MEAN |
| SECONDARY | Mean Change in CDASI From Start to End of Zetomipzomib (KZR-616) Treatment | 16 weeks in each Treatment Period (32 weeks total) | This measure was only performed for patients with DM. | score on a scale | MEAN |
| SECONDARY | Mean Change in PP-NRS From Start to End of Zetomipzomib (KZR-616) Treatment | 16 weeks in each Treatment Period (32 weeks total) | This measure was only performed for patients with DM. | score on a scale | MEAN |
| SECONDARY | PK of Zetomipzomib [KZR-616] (Cmax) | Up to 5 hours | ng/mL | GEOMETRIC_MEAN | |
| SECONDARY | PK of Zetomipzomib [KZR-616] (Tmax) | Up to 5 hours | hours | GEOMETRIC_MEAN | |
| SECONDARY | PK of Zetomipzomib [KZR-616] (AUC) | Up to 5 hours | ng*h/mL | GEOMETRIC_MEAN | |
| SECONDARY | PK of KZR-59587 (Cmax) | Up to 5 hours | ng/mL | GEOMETRIC_MEAN | |
| SECONDARY | PK of KZR-59587 (Tmax) | Up to 5 hours | hours | GEOMETRIC_MEAN | |
| SECONDARY | PK of KZR-59587 (AUC) | Up to 5 hours | ng*h/mL | GEOMETRIC_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04033926/outcomes